Liminatus Pharma, Inc. (LIMN) Form 8-K — Jul 6, 2026
Liminatus Pharma completed its acquisition of InnocsAI LLC on July 2, 2026, pursuant to an Amended and Restated Merger Agreement. The transaction closed prior to receiving stockholder approval, allowing the immediate acquisition of InnocsAI's CAR-T therapy technology assets and intellectual property. The total consideration for the transaction consists of 1.6 billion shares of Liminatus common stock, valued at $0.20 per share. To comply with Nasdaq listing rules regarding issuance without shareholder approval, 11,188,729 shares of common stock and 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock were issued at closing.
Key figures
- Issuance Price
- 0.2
- Conversion Ratio
- 10000
- Common Stock Issued
- 11188729
- Nasdaq Issuance Cap
- 19.99%
- Merger Consideration Shares
- 1600000000
Price after filing
Close on the filing date to close N calendar days later (from $0.14). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.